BPC-157 / TB-500 20mg

The BPC-157 / TB-500 blend (also written BPC157 TB500) combines two of the most extensively studied repair-pathway peptides in a single pre-mixed liquid peptide solution in a 3ml research cartridge. Manufactured in the UK and supplied ready to use, with no reconstitution step, this BPC-157 TB-500 blend has become a frequent starting point for UK researchers investigating combined angiogenic, cytoprotective and cytoskeletal repair pathways.

BPC-157 — Angiogenic and Cytoprotective Mechanisms

BPC-157 is a synthetic pentadecapeptide, a partial sequence of a gastric protective protein found in human gastric juice, first isolated in the 1990s. Its most extensively documented research pathway involves upregulation of vascular endothelial growth factor (VEGF) and its receptor VEGFR2, promoting new capillary formation into damaged tissue. Studies have also examined its interaction with the nitric oxide system, including upregulation of endothelial nitric oxide synthase (eNOS), contributing to vasodilation and endothelial protection alongside its angiogenic effects.

Beyond angiogenesis, preclinical research has explored BPC-157's involvement in FAK-paxillin focal adhesion signalling and Egr-1 transcription factor activity, both relevant to endothelial cell migration and early tissue scaffolding after injury. A separate and consistently replicated body of research has examined possible interactions with growth hormone receptor expression, with some studies suggesting downstream amplification of IGF-1 signalling in target tissues. Reflecting its origin in gastric juice protein, BPC-157 has also been studied extensively in gastrointestinal models, including mucosal barrier integrity and gut lining research.

TB-500 — Actin Sequestration and Cell Migration

TB-500 is a synthetic peptide corresponding to the actin-binding domain of Thymosin Beta-4, a naturally occurring 43-amino-acid protein. Its core, well-characterised mechanism is the sequestration of monomeric G-actin via the LKKTETQ binding motif, holding a reversible pool of unpolymerised actin that cells can rapidly mobilise into filamentous F-actin at the leading edge when migration signals are received. This underpins the formation of lamellipodia and filopodia, the structural extensions cells use to move directionally into a wound site.

Beyond its structural role in actin dynamics, TB-500 research has examined activation of the integrin-linked kinase (ILK) and downstream Akt signalling pathway, associated with cell survival and migration in tissue-repair models. Separately, thymosin beta-4-related research has documented VEGF induction via a HIF-1α-dependent pathway, giving TB-500 a secondary angiogenic research relevance alongside its primary actin-sequestering mechanism.

Combined Repair-Pathway Research

Preclinical investigations using combined BPC-157 and TB-500 have focused on tendon-ligament-vasculature crosstalk in musculoskeletal injury models, examining whether BPC-157's angiogenic and growth-factor signalling combines with TB-500's actin-driven cell migration to produce effects beyond either peptide studied alone. Research interest in this pairing centres on the potential overlap between new vessel formation and the cellular motility required to populate a healing site, alongside the shared downstream involvement of VEGF signalling from both compounds via distinct upstream mechanisms.

Research Format and Quality Assurance

Pre-mixed as a combination in a 3ml research cartridge, this format is designed for UK researchers who wish to study both compounds simultaneously without a separate reconstitution step for each. Each batch is independently HPLC-tested for purity and mass-spectrometry confirmed for the identity of both peptides, with a lot-matched Certificate of Analysis issued for every order.

For laboratory research use only. Not intended for human or animal consumption.